FDC Q4 FY17 earnings call: Revenue & Margins
Q4 FY17 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on FDC Ltd's Q4 FY17 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
For Q4 FY 2017, total revenue was Rs. 256 Crs, up from Rs. 249 Crs in Q4 FY 2016.
From FDC Ltd's Q4 FY17 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- For Q4 FY 2017, total revenue was Rs. 256 Crs, up from Rs. 249 Crs in Q4 FY 2016.
- The year-on-year revenue growth for Q4 FY 2017 was 3.7%.
- Domestic sales reached Rs. 256 Crs in Q4 FY 2017 with a 3.7% growth, while the Indian Pharmaceutical Market (IPM) grew by 10.3% in the same period.
2 more points from FDC Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what FDC Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what FDC Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
Contact details for financial officers are provided for specific queries, implying detailed financial…
Locked: what FDC Ltd said on fundraising
Also locked on this page: margins, capex, order book
Free account, 30 seconds. No card needed.
Order Book & Pipeline
See what FDC Ltd said on order book & pipeline — free account, 30 seconds.
FDC Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹572 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What FDC's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Unichem Laboratories (Q4 FY17)
Quarter ended March 31, 2017 revenue from operations: INR 18,735 lakhs, up 7% YoY (from INR 17,447 lakhs in Q4 FY16) (Page 38). Key concall takeaways from…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
FDC Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were FDC Ltd Q4 FY17 results?
For Q4 FY 2017, total revenue was Rs. 256 Crs, up from Rs. 249 Crs in Q4 FY 2016.
What is FDC Ltd share price analysis?
FDC Ltd currently shows a neutral. The stock trades at a P/E of 18.6 with a market cap of ₹5,739 Cr. Investors should review the full earnings analysis for detailed insights.
Keep FDC Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.